RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  McLure, Kevin G ^a,b   Gesner, Emily M ^a,b   Tsujikawa, Laura ^a,b   Kharenko, Olesya A ^a,b   Attwell, Sarah ^a,b   Campeau, Eric ^a,b   Wasiak, Sylwia ^a,b   Stein, Adam ^c,d   White, Andre ^c   Fontano, Eric ^c   Suto, Robert K ^c   Wong, Norman C W ^a,b   Wagner, Gregory S ^a,b   Hansen, Henrik C ^a,b   Young, Peter R ^a,b  

^a Resverlogix Corp   (Canada)

^b Resverlogix Corp   (United States)

^c Xtal BioStructures Inc   (United States)

^d Cayman Chemical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 HYDROXYETHOXY) 3,5 DIMETHYLPHENYL] 5,7 DIMETHOXYQUINAZOLIN 4(3H)ONE; APOLIPOPROTEIN A1; BROMODOMAIN AND EXTRA TERMINAL PROTEIN; MEMBRANE PROTEIN; PROTEIN INHIBITOR; RVX 208; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG STRUCTURE; EPIGENETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTHERMAL TITRATION CALORIMETRY; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; THERMODYNAMICS; TRANSCRIPTION REGULATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; EPIGENESIS, GENETIC; HEPATOCYTES; HUMANS; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84896699624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083190     Document Type: Article

References (52)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681.
3. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA : the journal of the American Medical Association 302: 1993-2000.
4. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, et al. (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. Journal of the American College of Cardiology 51: 634-642. (Pubitemid 351186873)
5. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, et al. (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA : the journal of the American Medical Association 299: 2524-2532.
6. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine 357: 2109-2122. (Pubitemid 350146106)
7. Vaisar T (2012) Proteomics Investigations of HDL: Challenges and Promise. Current vascular pharmacology.
8. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. The New England journal of medicine 364: 127-135.
9. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, et al. (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arteriosclerosis, thrombosis, and vascular biology 30: 796-801.
10. Degoma EM, Rader DJ (2011) Novel HDL-directed pharmacotherapeutic strategies. Nature reviews Cardiology 8: 266-277.
11. Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, et al. (2012) Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clinical pharmacology and therapeutics 91: 109-122.
12. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, et al. (2011) Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA : the journal of the American Medical Association 306: 2099-2109.
13. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, et al. (2012) Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. European heart journal.
14. Creider JC, Hegele RA, Joy TR (2012) Niacin: another look at an underutilized lipid-lowering medication. Nature reviews Endocrinology.
15. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA: the journal of the American Medical Association 290: 2292-2300.
16. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, et al. (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA : the journal of the American Medical Association 297: 1675-1682.
17. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, et al. (2010) A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. Journal of the American College of Cardiology 55: 2727-2735.
18. Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, et al. (2010) RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. Journal of the American College of Cardiology 55: 2580-2589.
19. Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, et al. (2011) Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease: A Randomized Controlled Trial. Journal of the American College of Cardiology 57: 1111-1119.
20. Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, et al. (2012) ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy.
21. Hansen HC, Chopade SP, Citineni JR, Short RP, Yiannikouros GP (2012) Methods of preparing quinazolinone derivatives. US Patent 8,114,995: Resverlogix Corp., Canada.
22. Hansen HC (2011) Compounds for the prevention and treatment of cardiovascular diseases. US Patent 8,053,440: Resverlogix Corp., Canada.
23. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
24. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119-1123.
25. Taddei A, Maison C, Roche D, Almouzni G (2001) Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nature cell biology 3: 114-120. (Pubitemid 32118363)
26. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. Meth Enzymol 276: 307-326. (Pubitemid 27085611)
27. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of Macromolecular Structures by the Maximum-Likelihood method. Acta Crystallogr D 53: 240-255. (Pubitemid 27235885)
28. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ (2007) How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nature structural & molecular biology 14: 1025-1040. (Pubitemid 350060344)
29. Vidler LR, Brown N, Knapp S, Hoelder S (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. Journal of medicinal chemistry 55: 7346-7359.
30. Filippakopoulos P, Knapp S (2012) The bromodomain interaction module. FEBS letters 586: 2692-2704.
31. Mirguet O, Lamotte Y, Donche F, Toum J, Gellibert F, et al. (2012) From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151. Bioorganic & medicinal chemistry letters.
32. Chung CW, Coste H, White JH, Mirguet O, Wilde J, et al. (2011) Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. Journal of medicinal chemistry 54: 3827-3838.
33. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine 359: 2195-2207.
34. Cheng C, Noordeloos AM, Jeney V, Soares MP, Moll F, et al. (2009) Heme Oxygenase 1 Determines Atherosclerotic Lesion Progression Into a Vulnerable Plaque. Circulation 119: 3017-3027.
35. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, et al. (2008) Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review. PLoS Med 5: e78.
36. Collaboration IRGCERF (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. The Lancet.
37. Consortium I-RMRAIRM (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet.
38. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature reviews Drug discovery 3: 301-317. (Pubitemid 38499758)
39. Swinney DC, Anthony J (2011) How were new medicines discovered? Nature reviews Drug discovery 10: 507-519.
40. Stahelin HF (1996) The history of cyclosporin A (Sandimmune) revisited: another point of view. Experientia 52: 5-13.
41. Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. The Journal of antibiotics 28: 721-726.
42. Walsh CT, Zydowsky LD, McKeon FD (1992) Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. The Journal of biological chemistry 267: 13115-13118.
43. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909. (Pubitemid 21917235)
44. Kamanna VS, Kashyap ML (2008) Mechanism of action of niacin. The American Journal of Cardiology 101: 20B-26B.
45. Mrowietz U, Asadullah K (2005) Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends in molecular medicine 11: 43-48. (Pubitemid 40092674)
46. Zhu YX, Kortuem KM, Stewart AK (2012) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leukemia & lymphoma.
47. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nature reviews Drug discovery 5: 37-50.
48. Dawson MA, Kouzarides T, Huntly BJ (2012) Targeting epigenetic readers in cancer. The New England journal of medicine 367: 647-657.
49. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nature reviews Drug discovery 11: 384-400.
50. Clinical trials website. Available: NCT01587703 (2012) A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers 2012 ed: www.clinicaltrials.gov. Accessed 2013 June 20.
51. Clinical trials website. Available: NCT01713582 (2012) A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015 in Haematological Malignancies. www.clinicaltrials.gov. Accessed 2013 June 20.
52. Engh RA, Huber R (1991) Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr A 47: 392-400.